EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan
Open Access
- 30 September 2019
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (6) , 6090-6100
Abstract
Malignant cancer is the top cause of mortality in Taiwan. In particular, the mortality rate of with lung cancer reached 39.2/100,000 in 2017. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are being increasingly used to treat lung cancer.; however, due to small sample sizes and a limited number of adequately controlled studies, it is difficult to compare survival rates of traditional chemotherapy with EGFR-TKI therapy when used as a first-or second-line treatment for patients with lung cancer, and therefore data on its efficacy are inconclusive. Therefore, Taiwan's entire 2010-2015 National Health Insurance Database (NHID) was used to perform a retrospective study. The top two anti-neoplastic first-line therapies used for lung cancer were traditional platinum-based doublet chemotherapy and EGFR-TKI therapy. Patients with stage III and IV lung cancer undergoing first-line EGFR-TKI therapy exhibited improved overall survival rates. However, patients with stage I and II lung cancer demonstrated limited benefits. Patients with stage IIIB and IV EGFR mutation (-) patients did not benefit from treatment with EGFR-TKI therapy. The EGFR-TKI gefitinib may be more effective in patients with lung cancer than erlotinib, irrespective of whether patients had been previously treated or not. Patients treated with Gefitinib also exhibited improved survival rates compared with other frequently used chemotherapeutic drugs.Keywords
This publication has 21 references indexed in Scilit:
- Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer RegistryJournal of Thoracic Oncology, 2013
- Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialThe Lancet Oncology, 2013
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012European Journal of Cancer, 2013
- Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled TrialsPLOS ONE, 2012
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 studyThe Lancet Oncology, 2012
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRNew England Journal of Medicine, 2010
- Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis of Randomized TrialsJournal of Thoracic Oncology, 2009
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled TrialsJournal of Clinical Oncology, 2008
- Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published LiteratureJournal of Clinical Oncology, 2005